octreotide acetate

P=N/A, N=62, Not yet recruiting, Boston Children's Hospital

From August 2019 to October 2020, he received long-acting octreotide and transarterial chemoembolization (TACE), achieving stable disease...In September 2022, oral surufatinib was initiated but paused in September 2023 due to adverse effects...This case demonstrates that everolimus can induce SSTR re-expression in advanced, SSTR-negative pNETs, offering new therapeutic possibilities. The "induction plus re-evaluation" approach could guide personalized treatment strategies in late-stage pNETs, although further studies are needed to validate this approach.

P3, N=332, Active, not recruiting, Camurus AB | Trial completion date: Dec 2027 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026

Our findings suggest pasireotide LAR and pegvisomant as the most effective treatments for IGF-1 normalization. Pasireotide LAR was the best treatment for tumor shrinkage, though the evidence base was limited, requiring cautious interpretation. Their potential role as first-line options after surgery requires further research. Clinical decisions should consider cost, safety and patient-specific parameters to optimize outcomes.

P1, N=19, Completed, Roswell Park Cancer Institute | Recruiting --> Completed | N=14 --> 19 | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Feb 2025

Higher blood tumor mutational burden (bTMB) was linked to poor prognosis in Octreotide LAR-treated patients and correlated with higher Ki-67 levels, and alterations in the TM, mTOR, and Notch pathways...TERT mutations, bTMB, and MSAF predict PFS or OS. Co-occurring TM, mTOR, and NOTCH pathway alterations highlight ctDNA's potential in guiding precision medicine.

P=N/A, N=70, Active, not recruiting, Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2025 --> Dec 2025

Although AIP mutation-positive cases are typically resistant to SSAs, our patient carrying a novel AIP variant demonstrated a favorable response to SSA treatment.

She was started on long-acting octreotide due to reluctance for transsphenoidal surgery...These cases highlight the importance of screening all patients with pituitary lesions using an IGF-1 level regardless of presence of classical symptoms of acromegaly. On long-term follow-up, subclinical acromegaly after treatment has a relatively benign course without development of associated comorbidities, although additional studies involving large number of patients are needed.

P3, N=166, Recruiting, Grupo Espanol de Tumores Neuroendocrinos | Not yet recruiting --> Recruiting

P3, N=240, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Jul 2032 --> Jan 2034 | Trial primary completion date: Jun 2028 --> Sep 2030

177Lu-DOTATATE significantly extends progression-free survival (22.8 vs. 8.5 months) compared to octreotide LAR. Despite these advances, challenges remain, including treatment resistance and long-term toxicities. In this review, we explore advancements in specialized imaging techniques, rationale combination strategies, and exploring next-generation radiopharmaceuticals.